Skip to main content

Table 5 Common symptoms reported within 6 months before enrollment (≥15% of adult patients in either cohort)

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter, n (%)

rhPTH(1-84)

(n=60)

Conventional therapy

(n=571)

Analysis populationa

(N=631)

Fatigue

31 (51.7)

229 (40.1)

260 (41.2)

Paresthesia

31 (51.7)

169 (29.6)

200 (31.7)

Muscle twitching

29 (48.3)

125 (21.9)

154 (24.4)

Muscle cramping

25 (41.7)

193 (33.8)

218 (34.5)

Headache

20 (33.3)

105 (18.4)

125 (19.8)

Muscle pain

17 (28.3)

112 (19.6)

129 (20.4)

Brain fog

17 (28.3)

95 (16.6)

112 (17.7)

Muscle weakness

17 (28.3)

88 (15.4)

105 (16.6)

Tetany

17 (28.3)

71 (12.4)

88 (13.9)

Joint pain

16 (26.7)

138 (24.2)

154 (24.4)

Anxiety

16 (26.7)

118 (20.7)

134 (21.2)

Weakness in extremities

12 (20.0)

83 (14.5)

95 (15.1)

Pain in extremities

11 (18.3)

83 (14.5)

94 (14.9)

Bone pain

11 (18.3)

76 (13.3)

87 (13.8)

Constipation

11 (18.3)

72 (12.6)

83 (13.2)

Nausea

11 (18.3)

52 (9.1)

63 (10.0)

Back pain

9 (15.0)

106 (18.6)

115 (18.2)

  1. rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aThe assessment at enrollment (visit 1) was defined as baseline; pediatric patients (n=27), those who received rhPTH(1-34) (n=14), and those who initiated rhPTH(1-84) before enrollment (n=65) were excluded from the analysis